Calgary, Canada
Calgary, Canada
SEARCH FILTERS
Time filter
Source Type

Patent
Zenith Epigenetics | Date: 2017-04-20

The invention relates to substituted bicyclic compounds, which are useful for inhibition of BET protein function by binding to bromodomains, pharmaceutical compositions comprising these compounds, and use of the compounds and compositions in therapy.


Patent
Zenith Epigenetics | Date: 2017-03-15

The invention relates to substituted bicyclic compounds, which are useful for inhibition of BET protein function by binding to bromodomains, pharmaceutical compositions comprising these compounds, and use of the compounds and compositions in therapy.


Patent
Zenith Epigenetics | Date: 2017-10-11

The present disclosure relates to substituted pyridinones, which are useful for inhibition of BET protein function by binding to bromodomains, and their use in therapy.


Mendel D.B.,MedImmune LLC | Cherrington J.M.,Zenith Epigenetics | Laird A.D.,Pfizer
Clinical cancer research : an official journal of the American Association for Cancer Research | Year: 2015

The article by Mendel and colleagues, published in the January 1, 2003, issue of Clinical Cancer Research, described their novel preclinical approach to developing a thorough understanding of the exposure-activity relationship for sunitinib, a multitargeted receptor tyrosine kinase inhibitor being developed for oncology therapy. This work successfully set exposure guidelines to identify a biologically active dose in early clinical trials. ©2015 American Association for Cancer Research.


Patent
Zenith Epigenetics | Date: 2016-01-15

The present disclosure relates to compounds, which are useful for inhibition of BET protein function by binding to bromodomains, and their use in therapy.


Patent
Zenith Epigenetics | Date: 2014-07-30

The present disclosure relates to compounds, which are useful for inhibition of BET protein function by binding to bromodomains, and their use in therapy.


Patent
Zenith Epigenetics | Date: 2014-06-20

The invention relates to substituted bicyclic compounds, which are useful for inhibition of BET protein function by binding to bromodomains, pharmaceutical compositions comprising these compounds, and use of the compounds and compositions in therapy.


Patent
Zenith Epigenetics | Date: 2014-06-20

The invention relates to substituted bicyclic compounds, which are useful for inhibition of BET protein function by binding to bromodomains, pharmaceutical compositions comprising these compounds, and use of the compounds and compositions in therapy.


Patent
Zenith Epigenetics | Date: 2015-06-03

The present disclosure relates to compounds, which are useful for inhibition of BET protein function by binding to bromodomains, and their use in therapy.

Loading Zenith Epigenetics collaborators
Loading Zenith Epigenetics collaborators